Medicamen Biotech Limited (531146) Fair Value & Analysis
Healthcare · IN · Market cap ₹4.8B
Fair value as of: Jul 4, 2026
From 17 valuation models · updated today
Share price −1.4% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹224.25 – ₹422.73 · fair‑value band ₹74.19 – ₹98.91 · the ₹262.00 price screens above the ₹98.91 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Medicamen Biotech Limited (531146) currently trades at ₹262.00, while our model-based Fair Value estimate is ₹98.91 — implying the stock looks roughly 62.2% overvalued today. We read business quality at 35/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Medicamen Biotech Limited generated revenue of ₹1.2B at a net margin of 10.0%. Revenue declined 10.7% year over year. The stock trades on a trailing P/E of 37.5. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Medicamen Biotech Limited manufactures and sells pharmaceutical formulations in India. The company offers its products in various forms, including tablets, capsules, liquid and dry syrups, ointments, and oral rehydration solutions. It also provides oral rehydration solution, mouth wash, and dental care products. The company was founded in 1993 and is headquartered in New Delhi, India.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Medicamen Biotech Limited reported revenue of ₹1.6B in FY2025 versus ₹1.1B in FY2021, a compound +9.6%/yr. Reported net income was ₹71.1M in FY2025, compounding −12.5%/yr from FY2021.
Is 531146 fairly valued? → Check now
Similar stocks
6 more Drugs - Generic stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Indoco Remedies Limited 532612 | ₹244.55 | ₹96.79 | -60% |
| Anuh Pharma Limited 506260 | ₹80.21 | ₹110.37 | +38% |
| Coral Laboratories Limited 524506 | ₹605.55 | ₹779.49 | +29% |
| Gennex Laboratories Limited 531739 | ₹10.16 | ₹28.19 | +177% |
| Lactose (India) Limited 524202 | ₹103.75 | ₹130.91 | +26% |
| Beryl Drugs Limited 524606 | ₹21.22 | ₹17.12 | -19% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Medicamen Biotech Limited (531146) undervalued?
What is the fair value of 531146?
What is the quality score of 531146?
What is the revenue of Medicamen Biotech Limited (531146)?
What is the net profit margin of 531146?
Does Medicamen Biotech Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.